GAAP net loss per share was $(11.29) for Q2 2025, missing the consensus GAAP EPS estimate of $(4.62) by a wide margin, mainly due to a $17.0 million up-front license fee. NextCure advanced both its ...

R&D expense was $11.7 million for the three months ended June 30, 2025, compared to $7.6 million for the same period in 2024. The increase was primarily driven by higher research, development, ...

Plus: The August Full Sturgeon Moon shines, the colorful double star Albireo sparkles, and Mercury reappears in the sky this ...